<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119430</url>
  </required_header>
  <id_info>
    <org_study_id>HSP-2003-01</org_study_id>
    <nct_id>NCT01119430</nct_id>
  </id_info>
  <brief_title>Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder</brief_title>
  <official_title>Fluoxetine Versus Fluoxetine Plus DU125530 in Latency of Antidepressant Response Shortening in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether the speed of the clinical antidepressant
      action of fluoxetine can be accelerated by administering DU125530 a full 5-HT1A antagonist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SSRI acts by blocking the serotonin transporter (5-HT), increasing the availability of
      serotonin at the synaptic cleft averting its reuptake. The increment of serotonin activates
      5-HT1A presynaptic autoreceptors, resulting in a modulation in the release of serotonin by
      the presynaptic neuron. It is proposed that 5-HT1A receptor antagonism could accelerate the
      clinical effect of antidepressants by preventing this negative feedback.Preclinical data
      obtained with selective 5-HT1A antagonists, such as pindolol, and with mice lacking 5-HT1a
      receptors supports this hypothesis. Results on partial antagonists (pindolol) are conclusive
      in accelerating SSRI. It is reasonable to call into question whether a total antagonism of
      5-HT1a receptors could imply a more rapid antidepressant response. To test this hypothesis we
      conducted a double blind, randomised, controlled trial with DU 123550 added to fluoxetine 20
      mg/day
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    interim analysis suggested no differences with whole sample
  </why_stopped>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores on Hamilton Depression Rating Scale</measure>
    <time_frame>8 time points through 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Fluoxetine plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine plus DU125530</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU125530</intervention_name>
    <description>20mg/twice a day</description>
    <arm_group_label>Fluoxetine plus DU125530</arm_group_label>
    <other_name>Fluoxetine+DU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar pill as active comparator twice a day</description>
    <arm_group_label>Fluoxetine plus placebo</arm_group_label>
    <other_name>Fluoxetine+placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive eligible patients aged 18 to 70

          -  Diagnosis of unipolar major depression using DSM-IV criteria with moderate to severe
             symptoms (score e 18 on the Hamilton Depression Rating Scale-HDRS- of 17 items).

          -  There was a wash-out of 1 week of any antidepressant drug (specifically 28 days for
             fluoxetine) prior entering the study.

          -  Written informed consent was obtained from all participants.

        Exclusion Criteria:

          -  Concurrent psychiatric disorders (DSM IV axis I, II cluster A or B)

          -  Failure to respond to drug treatment in current depressive episode

          -  Previous resistance to SSRIs or other antidepressant drug

          -  Suicide risk score e 3 on the HDRS.

          -  Participation in other drug trials within the previous month

          -  Presence of delusions or hallucinations

          -  History of substance abuse (including alcohol) in the past three months

          -  Pregnancy or lactation

          -  Organic brain disease or history of seizures

          -  Serious organic illnesses such as hypo or hyperthyroidism,cardiac arrhythmias, asthma,
             diabetes mellitus.

          -  Myocardial infarction in the past 6 month

          -  Frequent or severe allergic reactions

          -  Concomitant use of other psychotropic drugs (benzodiazepines were allowed), lockers or
             catecholamine-depleting agents

          -  Current structured psychotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Pérez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatrist, Hospital de Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enric Álvarez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Departement, Psiquiatria, Hospital de Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolors Puigdemont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Psychiatrist, Hospital de Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josefina Pérez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatrist, Hospital de Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>May 6, 2010</last_update_submitted>
  <last_update_submitted_qc>May 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name_title>
    <organization>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</organization>
  </responsible_party>
  <keyword>major depression</keyword>
  <keyword>DU 125530</keyword>
  <keyword>Treatment depression</keyword>
  <keyword>Latency antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

